Protagonist Therapeutics Inc Stock News

Today, we revisit Protagonist Therapeutics for the first time in over a year and a half. The stock has cratered in recent trading sessions after the FDA put a clinical hold on a key study.

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (“Protagonist”

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTG

The FDA has placed a clinical hold on testing of rusfertide.

The FDA put a clinical hold on one of the biotech's new drug candidates.

The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) fell over 60% during intraday trading today. This is why it happened.

NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food a

NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Z

NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Res

NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwr

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p

NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underw

NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public of

Protagonist Therapeutics Inc (NASDAQ: PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a type of blood cancer. Data were presented at the